

09/08/2022

Dear Requester,

FOI 1539

Thank you for your Freedom of Information request which was received within the Trust.
Please note, this is a cross-site response for Bedford site and Luton site.

You asked:

Q1. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of melanoma?

- Nivolumab (monotherapy) **0 at Bedford.**
- Nivolumab AND Ipilimumab (combination) **0 at Bedford.**

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Please note, we do not treat melanoma at Luton.

Q2. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of Renal Cell Carcinoma?

- Nivolumab (monotherapy) **0 at Bedford**
- Nivolumab + Ipilimumab **0 at Bedford**
- Nivolumab + Cabozantinib **0 at Bedford**
- Avelumab + Axitinib **0 at Bedford**

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Please note, we do not treat renal cell carcinoma at Luton.

Q3. In the past 3 months, how many patients have been initiated* on the following agents for the treatment of upper gastrointestinal cancer (oesophagael cancer, gastric cancer and gastro-oesophageal junction cancer)?

- Nivolumab **1-5**
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) **1-5**

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q4. Does your trust participate in any clinical trials for the treatment of Melanoma? If so, please provide the name of each active trial, and the number of patients taking part.

No

Q5. Does your trust participate in any clinical trials for the treatment of Renal Cell Carcinoma? If so, please provide the name of each active trial, and the number of patients taking part.

No

This information is provided for your personal use and is the property of Bedfordshire Hospitals NHS Trust and subject to any existing Intellectual Property and Database Rights. Any commercial application or use of this information may be subject to the provisions of the Re-use of Public Sector Information Regulations 2015 (RPSI). This means that if you wish to re-use the information provided for commercial purposes for any reason you must ask the Trust for permission to do so.

Please note that the Trust has a formal internal review and complaints process which is managed by the Information Governance Manager/Data Protection Officer. Should you have any concerns with our response, you can make a formal request for an internal review. Requests *for internal review* should be submitted within three months of the date of receipt of the response to your original letter, and should be addressed to: dataprotectionofficer@ldh.nhs.uk. This option is available to you for up to three calendar months from the date your response was issued.

If you are not satisfied with the Trust review under the Freedom of Information Act 2000 you may apply directly to the Information Commissioners Officer (ICO) for a review of your appeal decision. The ICO can be contacted at: ICO, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF www.ico.org.uk

Yours sincerely,

FOI Officer

Bedfordshire Hospitals NHS Foundation Trust